Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?

Extending yesterday's gain, NRx Pharmaceuticals Inc NRXP stock is up more than 26% during the premarket trading on Friday.

NRx's stock opened Thursday up nearly 14% at $11.51 per share after closing Wednesday at $10.11 per share. The stock closed up 62.7% at $16.45 Thursday. Since Monday, the stock has gained almost 95%.

What happened during the week: Yesterday (Thursday), NRx announced it validated the first commercial formulation, with one year or greater stability, of its experimental COVID-19 treatment. NRx also said that it has "achieved a 30-to-50 fold increase" in the manufactured lot size of the drug.

It is developing Relief Therapeutics Holding AG's RLFTF Zyesami (RLF-100, aviptadil) as an intravenous treatment for respiratory failure in critically ill COVID-19 patients.

Earlier formulations of Zyesami were only stable for a few weeks.

Monday, the Company reported that Zyesami prevented the sharp rise in cytokines and was additionally associated with a significant decrease in 60-day mortality.

The next goal for NRx will be to win an emergency use authorization for Zyesami. The Company applied to the FDA for a EUA in June.

Price Action: NRXP shares are up 26% at $20.72 during the premarket session on the last check Friday.

Related content: Benzinga's Full FDA Calendar.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!